Dr. Petrylak on Trial of Atezolizumab in Urothelial Carcinoma
In Partnership With:
Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale School of Medicine, discusses the updates of a study of atezolizumab in patients with metastatic urothelial carcinoma (mUC).
Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale School of Medicine, discusses the updates of a study of atezolizumab in patients with metastatic urothelial carcinoma (mUC).
In this phase Ia study, patients with mUC who were previously treated with platinum-based chemotherapy received anti—PD-L1 therapy with atezolizumab at 15 mg/kg of 1200 mg intravenously every 3 weeks.
Long-term treatment with atezolizumab was well tolerated, showed durable responses, and extended overall survival by 27% (95% CI, 0.18-0.37).
